U.S. Water Utilities Stock News

Lucky Strike Entertainment (LUCK) shares moved 3% higher today, catching some attention from investors. While there wasn’t a high-profile catalyst, moves like this often have traders checking for clues about shifting sentiment or potential upcoming announcements. See our latest analysis for Lucky Strike Entertainment. While Lucky Strike Entertainment’s latest 3% jump puts some spark back in the share price, longer-term momentum has been mixed. The 7-day share price return of 8.3% suggests...

Marzetti (MZTI) just announced its 63rd consecutive year of raising its quarterly cash dividend. Shareholders are set to receive $1.00 per share next month. The company also filed a $255 million shelf registration related to an ESOP stock offering. See our latest analysis for Marzetti. Marzetti’s streak of dividend hikes comes as its share price has seen moderate ups and downs over the year, with a recent dip following news of the shelf registration and ESOP offering. Over the past year,...

Melco Resorts & Entertainment (NasdaqGS:MLCO) has announced it will close the Mocha Hotel Royal on 28 December 2025. This marks its third Mocha club closure. The company plans to reallocate gaming machines and reassign local staff to other casino operations. See our latest analysis for Melco Resorts & Entertainment. The closure news lands as Melco’s 2025 momentum is building, with a year-to-date share price return of nearly 62% and a 44% total return over twelve months. Although there has...

Kingsoft Cloud Holdings (NasdaqGS:KC) just released its third quarter earnings, showing notable revenue growth and a steep reduction in net loss compared to last year. This highlights clear progress in financial performance. See our latest analysis for Kingsoft Cloud Holdings. Kingsoft Cloud’s momentum has picked up notably this year, with a 77.6% one-year total shareholder return and the stock now trading at $12.45. While some short-term share price dips have occurred, the company’s...

International Bancshares (IBOC) has recently caught investors’ attention on valuation grounds. With the stock trading well below its estimated intrinsic value, many are taking a closer look at the company’s fundamentals and future prospects. See our latest analysis for International Bancshares. Despite a solid run over the last three years, with International Bancshares delivering a total shareholder return of 35.7%, the past year has seen sentiment cool as the 1-year total shareholder return...

In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway. This move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators. We'll explore how securing FDA...

In November 2025, Novavax announced at the Jefferies London Healthcare Conference that it is shifting its business model toward a greater focus on research and development through partnerships, especially with Sanofi, while raising its full-year 2025 adjusted revenue projection and forecasting US$610 million in Nuvaxovid sales. An intriguing outcome is that Novavax's move away from direct COVID-19 commercial operations has led to a notable increase in licensing and royalty revenues,...

Olema Pharmaceuticals recently completed a public offering, raising approximately US$218.5 million in gross proceeds through the sale of 11,500,000 common shares at US$19.00 per share. This capital injection, accompanied by multiple changes to the lead underwriting team, further positions the company for continued progress in its targeted oncology programs. We'll explore how the strengthened balance sheet from this offering shapes Olema Pharmaceuticals' investment narrative going...

LexinFintech Holdings Ltd. recently reported a net profit of RMB521 million for Q3 2025, achieving year-over-year profit growth, implementing a business model shift to comply with new lending regulations, and completing a US$25 million share buyback covering 2.35% of its shares. The company also raised its dividend payout ratio to 30%, reinforced risk management through enhanced AI capabilities, and reaffirmed its full-year guidance for significant net income growth. We’ll explore how...

Solventum Corporation (NYSE:SOLV) recently announced a share repurchase program authorizing the repurchase of up to US$1.00 billion of its common stock, with no expiration date, and as of October 31, 2025, had approximately 173.4 million shares outstanding. This substantial buyback, combined with ongoing acquisition activity, reflects Solventum’s intent to enhance shareholder value while bolstering its position in the healthcare sector. We will now explore how the share repurchase plan...

Earlier this month, the Missouri Public Service Commission approved a new large-load user rate structure for Ameren Missouri, requiring new, high-usage business customers to pay 100% of direct interconnection costs upfront and commit to long-term contracts. This measure aims to balance the integration of up to 2 gigawatts of new energy demand by 2032 while ensuring existing customers remain protected from costs, potentially influencing economic growth and future utility planning in...

Encompass Health Corp. and Vanderbilt Health recently announced plans to open a 40-bed inpatient rehabilitation hospital in Lebanon, Tennessee, and also unveiled a separate 50-bed hospital project in Fishers, Indiana, both aimed at serving patients with complex recovery needs. These expansion efforts further expand Encompass Health's national footprint in specialized inpatient rehabilitation, highlighting strong demand for post-acute care and a continued focus on joint ventures with leading...

Synaptics (SYNA) has just teamed up with Qualcomm Technologies to advance the integration of touch and fingerprint sensors in mobile and computing devices. This collaboration is drawing attention, particularly with the increasing focus on AI-powered user experiences. See our latest analysis for Synaptics. Synaptics’ headline-making partnership with Qualcomm arrives in the midst of a challenging year for shareholders, as the stock has posted a 1-year total shareholder return of -16.9% and a...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

NEXGEL, Inc. ( NASDAQ:NXGL ) shares have had a horrible month, losing 31% after a relatively good period beforehand...

As the U.S. stock market experiences a notable upswing with major indexes like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing significant gains entering the Thanksgiving holiday, investors are increasingly attentive to opportunities that may be trading below their estimated value. In such a buoyant environment, identifying stocks that are potentially undervalued can provide investors with strategic entry points to capitalize on broader market optimism while maintaining a focus...

As the U.S. stock market experiences a significant upswing, with major indexes like the Nasdaq and S&P 500 posting notable gains, investors are keenly observing growth companies that exhibit strong insider ownership. In such a buoyant market environment, stocks where company insiders hold substantial stakes can be appealing as they often signal confidence in the company's future prospects and alignment of interests with shareholders.

As the U.S. stock market continues its upward trajectory, with major indexes marking their biggest weekly rise since June, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, a term that may seem outdated yet remains significant, represent smaller or newer companies that can potentially offer substantial returns when they are built on solid financial foundations. In this article, we will explore three penny stocks that exhibit strong...

As major U.S. stock indices, including the Dow Jones, Nasdaq, and S&P 500, continue to experience gains entering the Thanksgiving holiday week, investors are keenly observing market dynamics that could impact small-cap stocks. With economic indicators showing mixed signals and broader market sentiment fluctuating, identifying promising yet lesser-known stocks becomes crucial for those looking to capitalize on potential opportunities in a dynamic environment.

As the U.S. stock market experiences a notable upswing, with major indices like the Dow Jones, S&P 500, and Nasdaq showing significant gains entering the Thanksgiving holiday, investors are increasingly eyeing opportunities for stable income amid this positive momentum. In such an environment, dividend stocks can offer a reliable source of income through regular payouts while potentially benefiting from capital appreciation as markets rise.

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics recently announced the initiation of a rolling New Drug Application submission to the U.S. FDA for accelerated approval of zipalertinib, targeting EGFR exon 20 insertion-mutated non-small cell lung cancer after chemotherapy. This milestone builds on zipalertinib’s Breakthrough Therapy Designation and leverages data from the REZILIENT1 Phase 1/2 trial involving previously treated patients. We'll explore how progress toward FDA...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Six Flags Entertainment Corporation has announced the appointment of John Reilly as its new Chief Executive Officer and President, effective December 8, 2025, following a comprehensive board-led succession process. This leadership transition brings industry veteran Reilly to the helm as the company seeks to address recent operational challenges and has gained support from major shareholders, including activist investor JANA Partners. We’ll examine how John Reilly’s operational expertise and...

Oruka Therapeutics reported encouraging phase 1 results for its psoriasis drug candidate, ORKA-001. The data suggest a long half-life and strong, sustained inhibition of STAT3 signaling, along with a favorable safety profile. See our latest analysis for Oruka Therapeutics. These encouraging trial results have energized investor sentiment, fueling a 99.87% share price return over the past 90 days and lifting the stock to $30.52. Momentum has clearly been building, with a total shareholder...